Citation Tools

PDF
FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

Download to a citation manager

Cite this article as:
Smolen J, Choe J, Prodanovic N, et al
FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study